A Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in the Treatment of Ph Positive Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring
Latest Information Update: 05 Mar 2024
At a glance
- Drugs Flumbatinib (Primary) ; Asparaginase; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Dexamethasone; Doxorubicin; Folinic acid; Mercaptopurine; Mesna; Methotrexate; Prednisone; Vincristine
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
Most Recent Events
- 22 Mar 2022 Planned End Date changed from 1 May 2022 to 30 Dec 2022.
- 22 Mar 2022 Planned primary completion date changed from 1 Mar 2022 to 30 Dec 2022.
- 08 May 2020 New trial record